Existing investor Novartis has committed to a $10m private placement alongside the IPO, in which the fibrosis therapy developer, based on UCSF research, is set to raise up to $96m.

Pliant Therapeutics, a US-based fibrosis drug developer based on research at University of California, San Francisco, set the terms for an initial public offering on Tuesday that will raise $96m at the top of its range. The company plans to issue 6 million shares priced between $14 and $16 each on the Nasdaq Global Market.…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.